Sign Out
Each modified-release tablet contains Trimetazidine HCl, BP 35 mg.
Trimetazidine is a metabolic agent, a specific and selective inhibitor of enzymes of the fatty acid β-oxidation. The 3-ketoacyl CoA thiolase. This inhibition of β-oxidation allows a recoupling of glycolysis and an increase in glucose oxidation for better energy production under ischemic conditions.
Continue with Google